Clinical Trials Feasibility Planning in Pancreatic Cancer
Pancreatic cancer is one of the deadliest cancers, not often detected in its early stages, developing in the pancreas and typically spreading rapidly to nearby organs. According to the American Cancer Society (ACS), about 56,770 people (29,940 men and 26,830 women) in the US will be diagnosed with pancreatic cancer in 2019. Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. Pancreatic cancer thus warrants clinical investigations for new drugs to fulfil the unmet medical need.
Oncology in general has been repeatedly found to have the lowest clinical trial success rates out of any therapeutic area. In particular pancreatic cancer was found to have the lowest Phase III-pre registration phase transition success rate (PTSR) (Source: Likelihood of Approval, Pharma Intelligence Center) compared to that for the other top five leading causes of cancer deaths predicted by the ACS for 2019 (lung, breast, prostate and colorectal). The current PTSR for pancreatic cancer is 80% for Phase I-Phase II, dropping dramatically to 32% for Phase II-Phase III and finally to 27% for Phase III-Pre-Registration. The likelihood of approval is also the lowest from Phase I through to Phase III for these same top five indications.
There are currently 910 ongoing clinical trials for Pancreatic Cancer worldwide and 208 trials planned. There is also a large portion, 495 trials or 15% of all trials, which have been suspended, terminated or withdrawn for a variety of reasons. Trial success can be affected by geography, competition, investigator and site choices. Low patient accrual can lead to costly delays in the eventual drug launch and revenue.
In this webinar Brooke Wilson, Associate Director at GlobalData, will present an analysis of the clinical trial feasibility for pancreatic cancer, compiled by utilizing the Trials Intelligence platform on the GlobalData Pharma Intelligence Center. Revati Tatake, Global Director at GlobalData, will moderate a Q&A session following the presentation.
Presented by
Brooke Wilson,
Associate Director, Trials Intelligence
Brooke Wilson, BSc Biotech(Hons), is the Associate Director, Trials Intelligence at GlobalData in Washington, D.C., where she is responsible for the development and enhancement of the clinical trials intelligence database. Prior to GlobalData, Brooke was the Head, Lead Sheet at PharmSource for 12 years where she gained solid experience in every aspect of drug development and drove the content and production of the Lead Sheet product. Brooke managed and trained analysts and worked with software developers for product enhancements based on clients’ needs. She has experience in interacting with clients and working with sales as a Lead Sheet technical expert. Brooke graduated from the University of Newcastle, Australia, with a BSc in Biotechnology, followed by an Honors degree in Biotechnology with a thesis focused on intestinal bacteria.
Revati Tatake,
Global Director, Databases and Analytics
Revati Tatake, PhD, is the Global Director of Databases and Analytics at GlobalData in New York City, where she is responsible for the development and continuous enhancement of databases in the company’s Pharma Intelligence Center. Revati has diverse experience, both in academic research and the healthcare industry, where she worked on several research, drug discovery, and competitive intelligence projects across many therapeutic areas. Before joining GlobalData, Revati worked at Citeline, where she was involved in competitive intelligence and analytics of clinical trials and products in the areas of Autoimmune/Inflammation, CNS, and Ophthalmology. Previously she worked at Boehringer Ingelheim Pharmaceuticals for over 10 years, where, as a Senior Principal Scientist, she led drug discovery projects involving traditional high-throughput screening, as well as innovative approaches for gene and cell therapies. She is a co-inventor on many issued US patents and applications related to projects on cell and gene therapies. Revati holds a PhD in Tumor Immunology from the Tata Cancer Research Institute in Mumbai, India. She was also a postdoctoral fellow at the University of Connecticut Health Center.